Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: A phase I/IIa study

International Archives of Allergy and Immunology

Volumn 154, Issue 4, 2011, Pages 336-344

  Pfaar, Oliver ^a   Barth, Christine ^a   Jaschke, Christine ^a   Hörmann, Karl ^a   Klimek, Ludger ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adjuvant; Allergic rhinitis; Grass pollen; Monophosphoryl lipid A; Sublingual immunotherapy

Indexed keywords

GRASS POLLEN EXTRACT; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PHL P 1 ANTIGEN; PHOSPHORYL LIPID A; PLACEBO; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ADULT; ALLERGY TEST; ARTICLE; BURNING SENSATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAY FEVER; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MOUTH BURNING SENSATION; MOUTH DISEASE; MOUTH SWELLING; NASAL DRYNESS; NAUSEA; NOSE CONGESTION; NOSE DISEASE; ORAL PRURITUS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POLLEN ALLERGY; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; SNEEZING; SUBLINGUAL IMMUNOTHERAPY; SWELLING; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, SUBLINGUAL; ALLERGENS; ANTIGENS, PLANT; DESENSITIZATION, IMMUNOLOGIC; HUMANS; LIPID A; MIDDLE AGED; NASAL PROVOCATION TESTS; POACEAE; POLLEN; RHINITIS, ALLERGIC, SEASONAL;

EID: 77958150039     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321826     Document Type: Article

References (45)

1. Bousquet J, Lockey RF, Malling HJ: WHO Position Paper: Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53:1-48.
2. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Host A, Koivikko AS, Norberg LA, Valovirta E, Wahn U, Moller C: Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007;62:943-948. (Pubitemid 47037870)
3. Passalacqua G, Canonica GW: Long-lasting clinical efficacy of allergen specific immunotherapy. Allergy 2002;57:275-276. (Pubitemid 34280652)
4. Reha CM, Ebru A: Specific immunotherapy is effective in the prevention of new sensitivities. Allergol Immunopathol (Madr) 2007;35:44-51. (Pubitemid 46846606)
5. Amin HS, Liss GM, Bernstein DI: Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006;117:169-175. (Pubitemid 43017156)
6. Dahl R, Kapp A, Colombo G, de Monchy JGR, Rak S, Emminger W, Fernandez Rivas M, Ribel M, Durham SR: Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434-440. (Pubitemid 44160721)
7. Didier A, Malling HJ, Worm M, Horak F, Jager S, Montagut A, Andre C, de Beaumont O, Melac M: Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338-1345. (Pubitemid 350225683)
8. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S: Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802-809.
9. Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaumont O, Le Gall M: Efficacy and safety of 5-grass pollen sublingual immunotherapy tablets in pediatric allergic conjunctivitis. J Allergy Clin Immunol 2009;123:160-166.
10. Romagnani S: Immunologic influences on allergy and the Th1/Th2 balance. J Allergy Clin Immunol 2004;113:395-400.
11. Malling H, Weeke B: Position paper: immunotherapy. (EAACI) The European Academy of Allergology and Clinical Immunology. Allergy 1993;48(14 suppl):7-35.
12. Schmidt-Weber CB, Blaser K: Immunological mechanisms in specific immunotherapy. Springer Semin Immunopathol 2004;25:377-390.
13. Till SJ, Francis JN, Nouri-Aria K, Durham SR: Mechanisms of immunotherapy. J Allergy Clin Immunol 2004;13:1025-1034. (Pubitemid 38857978)
14. Thunberg S: Immune regulation by CD4+ CD25+ T cells and interleukin-10 in birch pollen-allergic patients and non-allergic controls. Clin Exp Allergy 2007;37:1127-1136.
15. Schmidt-Weber CB, Blaser K: New insights into the mechanisms of allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 2005;5:525-530. (Pubitemid 41679988)
16. Till SJ, Durham SR: Immunologic responses to subcutaneous allergen immunotherapy. Clin Allergy Immunol 2008;21:59-70.
17. Akdis CA, Akdis M: Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol 2009;123:735-746.
18. Cosmi L, Santarlasci V, Angeli R, Liotta F, Maggi L, Frosali F, Rossi O, Falagiani P, Riva G, Romagnani S, Annunziato F, Maggi E: Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10 production. Clin Exp Allergy 2006;36:261-272.
19. Frati F, Moingeon P, Marcucci F, Puccinelli P, Sensi L, Di CG, Incorvaia C: Mucosal immunization application to allergic disease: sublingual immunotherapy. Allergy Asthma Proc 2007;28:35-39.
20. Di Gioacchino M, Perrone A, Petracarca C, Di CF, Mistrello G, Falagiani P, Dadorante V, Verna N, Braga M, Ballone E, Cavallucci E: Early cytokine modulation after the rapid induction phase of sublingual immunotherapy with mite monomeric allergoids. Int J Immunopathol Pharmacol 2008;21:969-976.
21. Ciprandi G, Fenoglio D, Cirillo I, Vizzaccaro A, Ferrera A, Tosca MA, Puppo F: Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol 2005;95:38-44. (Pubitemid 41022771)
22. O'Hehir RE, Gardner LM, de Leon MP, Hales BJ, Biondo M, Douglass JA, Rolland JM, Sandrini A: House dust mite sublingual immunotherapy. The role for transforming growth factor-β and functional regulatory T cells. Am J Respir Crit Care Med 2009;180:936-947.
23. Savolainen J, Jacobsen L, Valovirta E: Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 2006;61:1184-1190. (Pubitemid 44326353)
24. Bohle B, Kinaciyan T, Gerstmayer M, Radakovics A, Jahn-Schmid B, Ebner C: Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007;120:707-713. (Pubitemid 47320765)
25. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F: A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001;56:498-505. (Pubitemid 32521429)
26. Mothes N, Heinzkill M, Drachenberg KJ, Sperr WR, Kraut MT, Majlesi Y, Semper H, Valent P, Neiderberger V, Kraft D, Valenta R: Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy 2003;33:1198-1208. (Pubitemid 37108522)
27. Patel P, Salapatek AMF: Pollinex Quattro: a novel and well-tolerated ultra-short-course allergy vaccine. Expert Rev Vaccines 2006;5:617-629. (Pubitemid 46021044)
28. Baldridge J, McGowan P, Evans J, Cluff C, Mossman S, John son D, Persing D: Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 2004;7:1129-1138.
29. Puggioni F, Durham SR, Francis JN: Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy 2005;60:678-684. (Pubitemid 40562476)
30. Allam JP, Peng WM, Appel T, Wenghoefer M, Neiderhagen B, Beiber T, Berge S, Novak N: Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J Allergy Clin Immunol 2008;121:368-374.
31. de Graaf-in't VC, Garrelds IM, van Toorenenbergen AW, Gerth van WR: Nasal responsiveness to allergen and histamine in patients with perennial rhinitis with and without a late phase response. Thorax 1997;52:143-148.
32. Boot JD, Chandoesing P, de Kam ML, Mascelli MA, Das AM, Gerth van Wijk R, de Groot H, Verhoosel R, Hiemstra PS, Diamant Z: Applicability and reproducibility of biomarkers for the evaluation of anti-inflammatory therapy in allergic rhinitis. J Investig Allergol Clin Immunol 2008;8:433-442.
33. Riechelmann H, Bachert C, Goldschmidt O, Hauswald B, Klimek L, Schlenter WW, Tasman AJ, Wagenmann M: Application of the nasal provocation test on diseases of the upper airways. Position paper of the German Society for Allergology and Clinical Immunology (ENT Section) in cooperation with the Working Team for Clinical Immunology (in German). Laryngorhinootologie 2003;82:183-188.
34. Van Overtvelt L, Lombardi V, Razafindratsita A, Saint-Lu N, Horoit S, Moussu H, Mascarell L, Moingeon P: IL-10-Inducing adjuvants enhance sublingual immunotherapy efficacy in a murine asthma model. Int Arch Allergy Immunol 2008;145:152-162.
35. Mascarell L, Van Overtvelt L, Lombardi V, Razafindratsita A, Moussu H, Horiot S, Chabre H, Limal D, Moutel S, Bauer J, Chiavaroli C, Moingeon P: A synthetic triacylated pseudo-dipeptide molecule promotes Th1/TReg immune responses and enhances tolerance induction via the sublingual route. Vaccine 2007;26:108-118. (Pubitemid 350213205)
36. Lombardi V, Van Overtvelt L, Horoit S, Moussu H, Chabre H, Louise A, Balazuc AM, Mascarell L, Moingeon P: Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route. Clin Exp Allergy 2008;38:1819-1829.
37. Wheeler AW, Elliott GT, Cybulski VA, Woroniecki SR: Sublingual immunotherapy adjuvanted with monophosphoryl lipid A. Allergy 2003;58(suppl 74):234.
38. Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA: Mechanisms of immune suppression by interleukin-10 and transforming growth factor-β: the role of regulatory cells. Immunology 2006;117:433-442.
39. Cox LS, Linnemann DL, Nolte H, Weldon D, Finegold I, Nelson HS: Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006;117:1021-1035. (Pubitemid 44308083)
40. Pfaar O, Klimek L: Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a doubleblind, placebo-controlled trial. Ann Allergy Asthma Immunol 2008;100:256-263. (Pubitemid 351398005)
41. Martin M, Michalek SM, Katz J: Role of innate immune factors in the adjuvant activity of monophosphoryl lipid A. Infect Immun 2003;71:2498-2507. (Pubitemid 36519862)
42. Wheeler AW, Marshall JS, Ulrich JT: A Th1- inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int Arch Allergy Immunol 2001;126:135-139. (Pubitemid 33135391)
43. Wilson D, Torres M, Durham SR: Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003;CD002893.
44. Urban E, Fischer von Weikersthal-Drachenberg KJ, Zielen S: Allergy vaccination in asthmatic subjects in a real-life setting (poster 674). Allergy 2007;62(suppl 83):244.
45. Rosewich M, Schulze J, Fischer von Weikersthal-Drachenberg KJ, Zielen S: Ultra-short course of immunotherapy in children and adolescents during a 3-yrs post-marketing surveillance study. Pediatr Allergy Immunol 2010;21:e185-e189. DOI: 10.1111/j.1399-3038.2009.00953.x.